Are Prothrombotic Mutations a Time-to-Event Risk Factor?
نویسندگان
چکیده
منابع مشابه
Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
CONTEXT Venous thrombosis is a common complication in patients with cancer, leading to additional morbidity and compromising quality of life. OBJECTIVE To identify individuals with cancer with an increased thrombotic risk, evaluating different tumor sites, the presence of distant metastases, and carrier status of prothrombotic mutations. DESIGN, SETTING, AND PATIENTS A large population-base...
متن کاملThrombophilic mutations are a main risk factor for placental abruption.
BACKGROUND AND OBJECTIVES The aim of the present study was to evaluate inherited thrombophilic factor V Leiden and factor II A20210 mutations in women presenting with abruption of a normally implanted placenta. DESIGN AND METHODS In a multi-center, case-control study, 50 consecutive women requiring immediate delivery because of abruption of the placenta were enrolled. Inclusion criteria were:...
متن کاملAre maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition characterized by thrombocytopenia in the newborn. If severe, the thrombocytopenia can lead to intracranial hemorrhage. FNAIT arises when maternal antibodies specific for platelet antigens, most commonly β3 integrin, cross the placenta and destroy fetal platelets. Surprisingly, few cases of FNAIT are associated with antibodies...
متن کاملRisk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A)
BACKGROUND AND PURPOSE Factor V Leiden and a prothrombin gene variant, G20210A, are mutations associated with a thrombotic risk. The aim of our study was to assess whether these mutations increase the risk of stroke in women under 45 years of age. METHODS We conducted a case-control study in western Washington state. Case patients were women aged 18 to 44 years with a first stroke (n = 106). ...
متن کاملHormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.
CONTEXT Estrogens are known to be prothrombotic, and findings from the Heart and Estrogen/progestin Replacement Study suggest that in women with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with early harm and late benefit in terms of coronary events. OBJECTIVE To assess whether, as hypothesized, prothrombotic mutations modify the association betwee...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Laboratory Medicine
سال: 2017
ISSN: 0007-5027,1943-7730
DOI: 10.1093/labmed/lmx046